<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Latex allergy: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Latex allergy: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Latex allergy: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert G Hamilton, PhD, DABMLI, FAAAAI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce S Bochner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Natural rubber latex (NRL) allergy is caused by sensitization to proteins in the sap-like fluid (latex) from the commercial rubber tree,
         <em>
          Hevea brasiliensis
         </em>
         (Hev b). Most patients are sensitized through exposure to NRL gloves or other dipped latex products (eg, dental dams, condoms, and balloons) in a medical or occupational setting.
        </p>
        <p>
         Since its first identification as a concern in the 1980s, the mainstay of management of latex allergy has been avoidance of latex products. Several other therapeutic approaches have been under investigation, including symptomatic pharmacotherapy, immunotherapy (IT), and anti-immunoglobulin E (IgE) therapy, but they have not shown promise.
        </p>
        <p>
         The management of latex allergy, including avoidance measures and experimental therapies that have been attempted, are reviewed here. Due to increase demand for locally produced personal protective equipment (including disposable gloves) as a result of the worldwide coronavirus disease 2019 (COVID-19) pandemic and other factors related to disposal issues, biodegradable properties, and climate change discussed in this review, it may be time to reconsider the use of a new generation of low-protein NRL medical gloves that meet rigorous performance and safety standards. An overview of latex processing and latex allergens and review of the epidemiology, clinical manifestations, and diagnosis of latex allergy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">
          "Latex allergy: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          OVERVIEW
         </span>
        </p>
        <p class="headingAnchor" id="H1949585133">
         <span class="h2">
          Types of allergic reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Latex allergy can involve delayed (type IV) or immediate type I reactions. Persons with delayed hypersensitivity that is manifested as a contact dermatitis associated with accelerator chemical sensitization are at increased risk for developing IgE-mediated (type I) systemic reactions. Thus, all persons with latex sensitivity, as documented by a positive
         <em>
          Hevea
         </em>
         latex-specific IgE antibody response, should be managed similarly.
        </p>
        <p class="headingAnchor" id="H3982012794">
         <span class="h2">
          Strategies for preventing or managing latex allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are four possible strategies for preventing or managing allergic symptoms once a person is diagnosed with latex allergy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoidance
         </strong>
         – The most effective and least expensive method is avoidance of natural rubber latex (NRL) allergen exposure [
         <a href="#rid1">
          1-4
         </a>
         ]. The prevalence of latex allergy among health care workers and the general public has dropped dramatically and, in some locations, to undetectable levels due to widespread avoidance measures involving a practical "latex-safe" (not "latex-free") environment strategy that has been adopted by most medical, dental, and nursing home facilities. (See
         <a class="local">
          'Institutional avoidance'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">
          "Latex allergy: Epidemiology, clinical manifestations, and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacotherapy
         </strong>
         – The treatment of acute and chronic allergic symptoms with pharmacotherapy is possible. However, prevention of reactions and the possibility of increased sensitization are preferred. Unfortunately, preventive pharmacotherapy is rarely effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunotherapy (IT)
         </strong>
         – The use of IT is limited due to the unavailability of approved therapeutic NRL extracts and a high frequency of adverse reactions when experimental extracts were used [
         <a href="#rid2">
          2,5,6
         </a>
         ]. (See
         <a class="local">
          'Immunotherapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anti-IgE therapy
         </strong>
         – Anti-IgE therapy is under investigation for use in patients with IgE-mediated latex allergy as an off-label indication [
         <a href="#rid7">
          7,8
         </a>
         ]. Anti-IgE is sometimes used together with an IT regimen. It is costly, and patients must have the appropriate body weight and total serum IgE level between 30 and 700 kU/L to be a candidate for
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H884140273">
         <span class="h1">
          INSTITUTIONAL AVOIDANCE
         </span>
        </p>
        <p class="headingAnchor" id="H2389677454">
         <span class="h2">
          Latex free versus latex safe
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a general misconception that a "latex-free" environment means one totally devoid of natural rubber latex (NRL) products. It conceptually remains a requirement to establish a safe environment for patients and employees who are sensitized (IgE antibody positive) to NRL allergens. A completely NRL-free environment is not practically achievable. In contrast, effective institutional avoidance of latex allergen has been accomplished by establishing a latex-safe environment that involves recognizing the importance of controlling latex allergen exposure for health care workers, the general public, and, more specifically, persons with NRL allergy.
        </p>
        <p class="headingAnchor" id="H3026351706">
         <span class="h2">
          Latex advisory committees
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most medical institutions established a latex committee and an institutional program to eliminate NRL allergen exposure [
         <a href="#rid3">
          3,9-11
         </a>
         ]. A multidisciplinary latex advisory committee typically has been composed of local experts with knowledge in legal matters, purchasing, occupational safety, allergy, and glove use, including surgery, medicine, and anesthesiology [
         <a href="#rid1">
          1,9,12,13
         </a>
         ]. While institutional latex advisory committees still exist on paper, most have not met in years because of the decline of latex allergy prevalence. Latex allergy has essentially disappeared from the general conscience of the medical and dental communities.
        </p>
        <p class="headingAnchor" id="H4221376868">
         <span class="h2">
          Latex-safe environmental policies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Establishment of latex-safe environmental policies involves replaci
         <em>
          ng Hevea
         </em>
         latex-containing products with non
         <em>
          -Hevea
         </em>
         -based synthetic products, if possible, or, at a minimum, identifying NRL products that do not release large quantities of latex allergen, such as powder-free latex gloves. Powder-free NRL products generally undergo extensive additional washes and a final chlorination step that removes
         <em>
          Hevea
         </em>
         -allergenic protein. (See
         <a class="local">
          'NRL product and environmental monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3061345112">
         <span class="h2">
          Medical/surgical gloves
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary source
         <em>
          of Hevea
         </em>
         latex exposure in medical institutions in the 1980 to 2010 period was the powdered medical examination/surgical glove (both nonsterile and sterile gloves) [
         <a href="#rid3">
          3,14,15
         </a>
         ]. The level of allergenic protein released from latex gloves can be determined [
         <a href="#rid16">
          16-18
         </a>
         ]. Some institutions have globally converted only their examination gloves to synthetic alternatives because examination gloves have higher NRL content than surgical gloves, while others have transitioned completely to n
         <em>
          on-Hevea
         </em>
         gloves [
         <a href="#rid4">
          4,9,11,13,19
         </a>
         ]. A small number of institutions have created a latex-"safer" environment by replacing all powdered latex gloves with low-allergen-containing, powder-free latex gloves that are less allergenic [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         It may be time to more broadly reconsider the use of particular NRL gloves that are documented to release low or no latex-allergenic protein based upon analytical documentation along with synthetic medical gloves, a particularly relevant consideration with increased glove demands during the coronavirus disease 2019 (COVID-19) pandemic. However, there is no universally accepted criterion, such as the use of &lt;0.15 mcg/g of glove of summed Hev b 1, 3, 5, and 6.02 allergens [
         <a href="#rid21">
          21
         </a>
         ], that has been adopted by manufacturers or regulators for defining a glove as having a low allergenic potential, although it is under consideration. In addition, the question remains whether a "lot" or "batch" of NRL gloves manufactured on a production line can be shown to have &lt;0.15 mcg/g of glove of summed Hev b allergen at the beginning, middle, and end of a run of thousands of gloves. (See
         <a class="local">
          'NRL product and environmental monitoring'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <em>
          Hevea
         </em>
         rubber stoppers (closures) have been the subject of intense debate. We and others have shown that puncturing a 100 percent NRL pharmaceutical vial closure can release low amounts of
         <em>
          Hevea
         </em>
         proteins into the pharmaceutical vial contents [
         <a href="#rid22">
          22
         </a>
         ]. The levels of allergen are low, can be detected by skin testing, and increase with each puncture. Due to this observation, pharmaceutical companies have mostly eliminated the concern by switching to the use of synthetic butyl rubber stoppers that contain no
         <em>
          Hevea
         </em>
         proteins. If there is a question by a pharmacist whether a particular vial contains a
         <em>
          Hevea
         </em>
         protein-containing latex stopper, they are encouraged to use the "one stick rule" that we have demonstrated provides the safest protocol for the administration of a pharmaceutical after puncturing through a
         <em>
          Hevea
         </em>
         latex stopper [
         <a href="#rid23">
          23
         </a>
         ]. For highly latex-allergic persons, injection of a drug containing
         <em>
          Hevea
         </em>
         proteins can evoke an allergic response, especially if administered intravenously. Thus, careful avoidance throughout their life is encouraged since chronic reexposure will lead to resensitization. The low levels of
         <em>
          Hevea
         </em>
         latex released by puncturing a 100 percent NLR are, however, not considered a concern for eliciting de novo sensitization in an otherwise non-latex-allergic person.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1562213753">
         <span class="h2">
          High-risk health care workers and sensitized patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         For high-risk health care workers and sensitized patients, latex avoidance is critically important to reduce symptoms and further sensitization. Institutions that have an employee with latex allergy must adhere to strict policies. At a minimum, such policies should permit only the use of low-protein, powder-free latex products for all employees and latex-free products for sensitized persons. It is not acceptable to give special latex-free gloves only to the worker with latex allergy since their environment can endanger them if a coworker inadvertently us
         <em>
          es Hevea
         </em>
         allergen-rich gloves. Use of low-protein, powder-free latex gloves by coworkers decreases, but does not eliminate, symptoms in health care workers with latex allergy [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          NRL product and environmental monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measuring the release of
         <em>
          Hevea
         </em>
         allergens from various products (
         <a class="graphic graphic_table graphicRef59584" href="/z/d/graphic/59584.html" rel="external">
          table 1
         </a>
         ), particularly medical gloves, and airborne levels of these allergens in occupational settings, is critical to documenting the suitability of newer-generation low-protein natural rubber latex (NRL) medical gloves in a latex-safe work environments. This determination can be used to document that an institution has transitioned to latex-safe status.
        </p>
        <p>
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.astm.org%2F&amp;token=j%2BtF41plvYHq0KcVLVNCgqxYoZWYpmARqYeH577SuTY%3D&amp;TOPIC_ID=5554" target="_blank">
          ASTM International
         </a>
         (formerly the American Society for Testing Materials) has qualified three standardized assays for evaluating the relative safety of
         <em>
          Hevea
         </em>
         latex-containing products and aeroallergen environmental monitoring where
         <em>
          Hevea
         </em>
         latex products are used. Of these three assays, the immunoenzymetric assay (IEMA; ASTM D7427-08) is preferred because its results are most predictive of a product's latex "allergen" content. Other assays for
         <em>
          Hevea
         </em>
         allergens, such as the human IgE anti-latex-based competitive inhibition assay [
         <a href="#rid25">
          25
         </a>
         ], remain research tools in selected laboratories due to their requirement for large amounts of human IgE anti-latex-containing serum [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Hevea
          </em>
         </strong>
         <strong>
          allergens
         </strong>
         – Of the 15 known
         <em>
          Hevea
         </em>
         allergens [
         <a href="#rid27">
          27
         </a>
         ],
         <em>
          H. brasiliensis
         </em>
         (Hev b) 1, 3, 5, and 6.02 have been identified as the principal "indicator" allergens for monitoring products and environments (
         <a class="graphic graphic_table graphicRef71927" href="/z/d/graphic/71927.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid28">
          28,29
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">
          "Latex allergy: Epidemiology, clinical manifestations, and diagnosis", section on 'Hevea indicator allergens'
         </a>
         ). Two-site monoclonal antibody-based IEMAs (ASTM D7427-08) are established as standard methods that provide quantitative estimates of these indicator allergens in product extracts and environmental samples [
         <a href="#rid26">
          26,30
         </a>
         ]. The sum of the Hev b 1, 3, 5, and 6.02 content in physiologic extracts reflects the allergenic potential of a
         <em>
          Hevea
         </em>
         latex-containing product or environment [
         <a href="#rid21">
          21
         </a>
         ]. Quantification of Hev b 1 and Hevamine alone is insufficient to effectively assess rubber product allergen potency [
         <a href="#rid31">
          31
         </a>
         ]. Summed concentrations of Hev b 1, 3, 5, and 6.02 totaling &lt;0.15 mcg/g of glove were shown to have low allergenic potential as assessed independently by an IgE enzyme-linked immunosorbent assay (ELISA) inhibition assay [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An earlier study using an IgE antibody-based inhibition assay has suggested that a latex aeroallergen threshold of 0.5 nanograms/cubic meter of air indicates a safer work environment [
         <a href="#rid32">
          32
         </a>
         ]. However, threshold environmental determinations have not been qualified using the ASTM D7427-08 IEMAs for allergen content.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Hevea
          </em>
         </strong>
         <strong>
          antigens
         </strong>
         –
         <em>
          Hevea
         </em>
         proteins that elicit an antibody response can be detected with the ASTM D6499 antigen ELISA [
         <a href="#rid33">
          33,34
         </a>
         ]. The utility of this measurement depends on the ability of all
         <em>
          Hevea
         </em>
         allergenic proteins to elicit an antibody response that is detectable by the assay. Its major limitation is that it does not distinguish between latex allergens (IgE inducing) and nonallergenic antigens (non-IgE inducing), and, therefore, it only provides an indirect measure of the allergenic potential of a product or environment. Like the total protein assay, the
         <em>
          Hevea
         </em>
         antigen assay is not suitable for definitively identifying "latex-safe" products and environments that require the assessment of accurate allergen content.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Total protein
         </strong>
         – The modified Lowry test (ASTM D5712) was the first assay developed to monitor total
         <em>
          Hevea
         </em>
         protein in product extracts or environmental specimens [
         <a href="#rid33">
          33,35
         </a>
         ]. This assay, while the least expensive of the three tests, is the least useful for defining levels of
         <em>
          Hevea
         </em>
         allergenic protein as it has limited analytic sensitivity and is only able to quantify high levels of total extractable protein and does not discriminate between allergenic and nonallergenic
         <em>
          Hevea
         </em>
         proteins.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          <i>
           Hevea
          </i>
          latex alternatives
         </span>
         <span class="headingEndMark">
          —
         </span>
         Synthetic elastomers and a non-
         <em>
          Hevea
         </em>
         rubber (Yulex) have been developed for use as alternatives in the manufacturing of commercial "rubber-like" products:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common synthetic elastomers include butyl rubber, a completely petroleum-based product with no allergenic protein, polymers of 2-chlorobutadiene (neoprene), and copolymers of butadiene and acrylonitrile [
         <a href="#rid36">
          36
         </a>
         ]. The predominant nonsterile, nonlatex examination gloves used in medical institutions today are made of nitrile, neoprene, vinyl, or synthetic polyisoprene rubber that is extracted from oil. Their color (white, blue, purple, or green) is arbitrary and does not reflect the type of material in the glove. Different glove materials vary in terms of their ability to be sterilized and still maintain their barrier properties.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Historically, a non-
         <em>
          Hevea
         </em>
         source of natural rubber is the Guayule plant (
         <em>
          Parthenium argentatum
         </em>
         ) [
         <a href="#rid37">
          37,38
         </a>
         ]. The raw material extracted from the shrub has an ultra-low protein content. The proteins that are present display no apparent in vitro or in vivo cross-reactivity with
         <em>
          Hevea
         </em>
         latex allergens. Thus, Yulex-based rubber products should pose no risk to persons who are allergic to
         <em>
          Hevea
         </em>
         latex. In the United States, some Yulex-based products were cleared by the US Food and Drug Administration (FDA). As of 2021, the company making Guayale products converted from using
         <em>
          Parthenium
         </em>
         to low-protein
         <em>
          Hevea
         </em>
         latex from Central American sources to manufacture consumer products (eg, wet suits) and, in the future, medical gloves.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H448362142">
         <span class="h1">
          INDIVIDUAL AVOIDANCE
         </span>
        </p>
        <p class="headingAnchor" id="H2116243943">
         <span class="h2">
          General approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         All persons with latex allergy, whether or not they come in contact with potentially contaminated body fluids, should use only non-
         <em>
          Hevea
         </em>
         medical gloves. In addition to gloves, there are as many as 40,000 consumer products in home and medical/dental environments that may contain natural rubber latex (NRL) [
         <a href="#rid39">
          39,40
         </a>
         ]. Examples are listed in the table (
         <a class="graphic graphic_table graphicRef59584" href="/z/d/graphic/59584.html" rel="external">
          table 1
         </a>
         ). Latex-containing forms of these products should be avoided as well. In the United States,
         <em>
          Hevea
         </em>
         latex-containing medical devices must be labeled "containing natural rubber latex" with a medical alert boxed warning. Unfortunately, there is no requirement for companies to label rubber products with their latex protein content. Consumer products do not have the same stringent labeling requirement. However, many are labeled as containing latex, which refers to NRL.
        </p>
        <p class="headingAnchor" id="H934866622">
         <span class="h2">
          Duration of avoidance and reevaluation in persons with latex allergy
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is well established that employing a latex-safe environment in an institution leads to a decrease in latex-induced symptoms and reported employee and patient sensitivity. However, latex-specific IgE antibody can remain detectable for at least five years in the skin and blood of persons with latex allergy who avoid latex exposure [
         <a href="#rid3">
          3,4,11,25,41-43
         </a>
         ]. Thus, continued avoidance of allergen exposure is recommended. (See
         <a class="local">
          'Strategies for preventing or managing latex allergy'
         </a>
         above.)
        </p>
        <p>
         Reevaluation, principally by IgE anti-NRL serology assays, to assess continued sensitization is performed primarily for information since a previously sensitized person is at risk for resensitization. Thus, latex allergen avoidance precautions should still be followed even if subsequent serologic testing is negative. However, a negative repeat IgE anti-NRL serology analysis is comforting as it suggests that the potential for an allergic response resulting from an inadvertent latex allergen exposure is minimal.
        </p>
        <p>
         Repeat evaluations are typically performed just prior to a required medical or dental procedure to assess risk or during a yearly health checkup. IgE anti-latex serology is the only available evaluation test available in the US due to its well-documented inter-assay latex allergosorbent consistency and its ability to generate a semiquantitative (kUa/L) result. In vivo skin test methods are not available in the US, due to an absence of approved NRL skin test extracts. European medical institutions, in contrast, can perform both serology and puncture skin testing because of the availability of at least one well-characterized approved NRL extract.
        </p>
        <p class="headingAnchor" id="H3508694743">
         <span class="h1">
          ADDITIONAL MANAGEMENT ISSUES
         </span>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Workplace
         </span>
         <span class="headingEndMark">
          —
         </span>
         A systematic approach for managing a worker with suspected natural rubber latex (NRL) allergy begins with confirmation of the diagnosis of latex allergy using validated diagnostic methods [
         <a href="#rid1">
          1,12,19
         </a>
         ]. In the US, this is an IgE antibody analysis by one of several US Food and Drug Administration (FDA) cleared immunoassay auto-analyzers. In Europe, it can also involve the use of an NRL extract-based puncture skin test. Confirmation of latex sensitization can justify efforts put forth for cessation of further NRL exposure in the patient's workplace. (See
         <a class="medical medical_review" href="/z/d/html/5543.html" rel="external">
          "Latex allergy: Epidemiology, clinical manifestations, and diagnosis", section on 'Objective tests to demonstrate latex allergy'
         </a>
         .)
        </p>
        <p>
         Despite the extensive research on the diagnostic potential of the 15 well-characterized
         <em>
          Hevea
         </em>
         latex allergenic components, IgE antibody measurements specific for these individual latex allergen components do not increase diagnostic sensitivity for latex-driven occupational asthma compared with just detecting IgE antibody to the natural extract [
         <a href="#rid44">
          44
         </a>
         ]. IgE anti-latex component measurements do, however, aid in discriminating between different routes of latex allergen exposure (eg, inhalation [Hev b 5/6.02] versus mucosal contact [Hev b 1/3]).
        </p>
        <p>
         One must document that impairment and disability results from latex exposure in the workplace. The employer then needs to be educated about the patient's diagnosis and their responsibility to provide effective interventions to create a latex-safe environment. If the patient cannot be effectively accommodated, workers' compensation benefits and rehabilitation may be appropriate.
        </p>
        <p class="headingAnchor" id="H2018885927">
         <span class="h2">
          Schools
         </span>
         <span class="headingEndMark">
          —
         </span>
         A systematic approach for managing a confirmed NRL allergy in a student in a school program begins with development of an individualized health care plan and a schoolwide avoidance plan. Education of the student on self-management skills is vital if the child has a risk of anaphylaxis [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several measures for the person with latex allergy are recommended to prevent and manage allergic reactions [
         <a href="#rid39">
          39,46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A medical alert bracelet indicating latex allergy should be worn.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Self-injectable
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         should be prescribed for all persons with a clinical history of systemic reactions to latex. (See
         <a class="medical medical_review" href="/z/d/html/388.html" rel="external">
          "Prescribing epinephrine for anaphylaxis self-treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/392.html" rel="external">
          "Anaphylaxis: Emergency treatment", section on 'Epinephrine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonlatex gloves should be carried.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients should report their allergy prior to any medical, dental, gynecologic, or surgical procedure and request a latex-safe environment [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2081.html" rel="external">
          "Perioperative anaphylaxis: Evaluation and prevention of recurrent reactions", section on 'Latex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Immunotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of immunotherapy (IT) for the treatment of IgE-mediated latex allergy is limited by the absence of regulator-approved extracts and the frequency and severity of reactions to IT [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Several small, randomized trials were performed with conventional subcutaneous immunotherapy (SCIT) using crude latex extracts [
         <a href="#rid48">
          48-50
         </a>
         ]. Efficacy was variable. One trial demonstrated decreased symptoms of urticaria and rhinoconjunctivitis but not asthma [
         <a href="#rid48">
          48
         </a>
         ], whereas another did show reduced airway hyperreactivity to latex [
         <a href="#rid49">
          49
         </a>
         ]. A third trial failed to demonstrate any difference in medication use or symptom scores [
         <a href="#rid50">
          50
         </a>
         ]. A high frequency of adverse events, including systemic reactions, was reported in all studies. In one trial, adverse events occurred with similar frequency in both the induction and maintenance phases of the regimen [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Some studies suggest that the frequency and severity of adverse events are lower with sublingual immunotherapy (SLIT) compared with SCIT [
         <a href="#rid51">
          51-55
         </a>
         ]. However, results vary, and anaphylaxis has been reported with SLIT [
         <a href="#rid56">
          56-59
         </a>
         ].
        </p>
        <p>
         Novel IT approaches are under investigation to decrease the risk of severe adverse reactions (allergenicity) and yet maintain or improve efficacy (immunogenicity). These approaches include recombinant allergens, T cell epitope-based peptides, and adjuvants that are conjugated to or coadministered with the allergen [
         <a href="#rid39">
          39,60
         </a>
         ]. These therapies are still in the experimental stages.
        </p>
        <p class="headingAnchor" id="H2931915810">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109412.html" rel="external">
          "Society guideline links: Latex allergy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoidance
         </strong>
         – Once latex allergy is diagnosed, avoidance should be instituted as the primary method of management. Pharmacotherapy, immunotherapy (IT), and anti-immunoglobulin E (IgE) therapy are not substitutes for effective avoidance. (See
         <a class="local">
          'Overview'
         </a>
         above and
         <a class="local">
          'Immunotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Institutional strategies
         </strong>
         – Institutional policy changes in the use of
         <em>
          Hevea
         </em>
         products can reduce occupational and patient exposures. One approach is to use the "one stick rule" for a patient who is highly allergic to latex when administering a pharmaceutical after puncturing through a
         <em>
          Hevea
         </em>
         latex stopper or when the stopper material is not known. Another is a universal criterion for insuring low allergenic potential of low-protein powder-free natural rubber latex (NRL) medical gloves. Once this is adopted by glove manufacturers and accepted by governmental regulators (eg, &lt;0.15 mcg per gram of glove of summed Hev b 1, 3, 5, and 6.02 allergens), it may be time to reconsider the reinstitution of these low-allergen NRL gloves back into institutions that have historically had a NRL-free policy. (See
         <a class="local">
          'Institutional avoidance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Individual strategies
         </strong>
         – Nonlatex-containing gloves should be used by persons with latex allergy who use protective gloves. In addition, use of low-powder latex gloves by coworkers decreases exposure and sufficiently decreases symptoms in the person with latex allergy in most cases. The policy of using of nonlatex gloves by all is poised to change once qualified low-allergen, low-protein, powder-free NRL gloves become available. Other latex-containing products should also be avoided. (See
         <a class="local">
          'Individual avoidance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of NRL allergens in products and the environment
         </strong>
         – Standardized assay methods for the quantification of allergenic
         <em>
          Hevea
         </em>
         proteins facilitate differentiating between highly allergenic
         <em>
          Hevea
         </em>
         -containing products and occupational environments and those with low allergenic potential. (See
         <a class="local">
          'NRL product and environmental monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Hevea
          </em>
         </strong>
         <strong>
          latex alternatives
         </strong>
         – Synthetics are alternative products are considered safe for use in
         <em>
          Hevea
         </em>
         -sensitized individuals. (See
         <a class="local">
          'Hevea latex alternatives'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional management measures
         </strong>
         – Additional measures advised for patients with latex allergy include having autoinjectable
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         available, carrying nonlatex gloves, wearing a medical alert bracelet, and requesting a latex-safe environment for procedures or employment. Although allergy to latex has decreased in prevalence, clinicians should not discount the risk of anaphylaxis in a patient with a "latex allergy" label that is reported in their medical record. (See
         <a class="local">
          'Individuals'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Bernstein DI. Management of natural rubber latex allergy. J Allergy Clin Immunol 2002; 110:S111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland MF, Suphioglu C, Rolland JM, O'Hehir RE. Latex allergy: towards immunotherapy for health care workers. Clin Exp Allergy 2002; 32:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly KJ, Wang ML, Klancnik M, Petsonk EL. Prevention of IgE Sensitization to Latex in Health Care Workers After Reduction of Antigen Exposures. J Occup Environ Med 2011; 53:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumchen K, Bayer P, Buck D, et al. Effects of latex avoidance on latex sensitization, atopy and allergic diseases in patients with spina bifida. Allergy 2010; 65:1585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolland JM, O'Hehir RE. Latex allergy: a model for therapy. Clin Exp Allergy 2008; 38:898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucera E, Schiavino D, Sabato V, et al. Sublingual immunotherapy for latex allergy: tolerability and safety profile of rush build-up phase. Curr Med Res Opin 2008; 24:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 2007; 93:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cusick C. A latex-safe environment is in everyone's best interest. Mater Manag Health Care 2007; 16:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SGNA Practice Committee. Guideline for preventing sensitivity and allergic reactions to natural rubber latex in the workplace. Gastroenterol Nurs 2008; 31:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly KJ, Sussman G. Latex Allergy: Where Are We Now and How Did We Get There? J Allergy Clin Immunol Pract 2017; 5:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein DI, Karnani R, Biagini RE, et al. Clinical and occupational outcomes in health care workers with natural rubber latex allergy. Ann Allergy Asthma Immunol 2003; 90:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremer R, Kleine-Diepenbruck U, Hering F, Holschneider AM. Reduction of latex sensitisation in spina bifida patients by a primary prophylaxis programme (five years experience). Eur J Pediatr Surg 2002; 12 Suppl 1:S19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yunginger JW, Jones RT, Fransway AF, et al. Extractable latex allergens and proteins in disposable medical gloves and other rubber products. J Allergy Clin Immunol 1994; 93:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kujala V, Alenius H, Palosuo T, et al. Extractable latex allergens in airborne glove powder and in cut glove pieces. Clin Exp Allergy 2002; 32:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truscott W. Glove powder reduction and alternative approaches. Methods 2002; 27:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh D, Ng V, Leow YH, Goh CL. A study of natural rubber latex allergens in gloves used by healthcare workers in Singapore. Br J Dermatol 2005; 153:954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palosuo T, Antoniadou I, Gottrup F, Phillips P. Latex medical gloves: time for a reappraisal. Int Arch Allergy Immunol 2011; 156:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown RH, Hamilton RG, McAllister MA, Johns Hopkins Latex Task Force. How health care organizations can establish and conduct a program for a latex-safe environment. Jt Comm J Qual Saf 2003; 29:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stinkens R, Verbeke N, Van de Velde M, et al. Safety of a powder-free latex allergy protocol in the operating theatre: A prospective, observational cohort study. Eur J Anaesthesiol 2019; 36:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palosuo T, Reinikka-Railo H, Kautiainen H, et al. Latex allergy: the sum quantity of four major allergens shows the allergenic potential of medical gloves. Allergy 2007; 62:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Primeau MN, Adkinson NF Jr, Hamilton RG. Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions. J Allergy Clin Immunol 2001; 107:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton RG, Brown RH, Veltri MA, et al. Administering pharmaceuticals to latex-allergic patients from vials containing natural rubber latex closures. Am J Health Syst Pharm 2005; 62:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nienhaus A, Kromark K, Raulf-Heimsoth M, et al. Outcome of occupational latex allergy--work ability and quality of life. PLoS One 2008; 3:e3459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith AM, Amin HS, Biagini RE, et al. Percutaneous reactivity to natural rubber latex proteins persists in health-care workers following avoidance of natural rubber latex. Clin Exp Allergy 2007; 37:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palosuo T, Alenius H, Turjanmaa K. Quantitation of latex allergens. Methods 2002; 27:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandenplas O, Raulf M. Occupational Latex Allergy: the Current State of Affairs. Curr Allergy Asthma Rep 2017; 17:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeang HY, Arif SA, Yusof F, Sunderasan E. Allergenic proteins of natural rubber latex. Methods 2002; 27:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sussman GL, Beezhold DH, Kurup VP. Allergens and natural rubber proteins. J Allergy Clin Immunol 2002; 110:S33.
          </a>
         </li>
         <li class="breakAll">
          ASTM D7427-08. Standard test method for immunological measurement of four principal allergenic proteins (Hev b 1, 3, 5, 6.02) in natural rubber and its products derived from latex. American Society for Testing Materials, International, West Conshohocken, PA, 19428.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee MF, Wang NM, Han JL, et al. Estimating allergenicity of latex gloves using Hev b 1 and hevamine. J Investig Allergol Clin Immunol 2010; 20:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baur X. I are we closer to developing threshold limit values for allergens in the workplace? Ann Allergy Asthma Immunol 2003; 90:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beezhold DH, Kostyal DA, Tomazic-Jezic VJ. Measurement of latex proteins and assessment of latex protein exposure. Methods 2002; 27:46.
          </a>
         </li>
         <li class="breakAll">
          ASTM D6499: Standard test method for the immunological measurement of antigenic protein in natural rubber and its products. American Society for Testing Materials, International, West Conshohocken, PA, 19428.
         </li>
         <li class="breakAll">
          ASTM D5712-05E1: Standard test method for analysis of aqueous extractable protein in natural rubber and its products using the modified Lowry method. American Society for Testing Materials, International, West Conshohocken, PA, 19428.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renaud MY. Composition of synthetic latexes used for manufacturing gloves by dipping processes. Clin Rev Allergy 1993; 11:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siler DJ, Cornish K, Hamilton RG. Absence of cross-reactivity of IgE antibodies from subjects allergic to Hevea brasiliensis latex with a new source of natural rubber latex from guayule (Parthenium argentatum). J Allergy Clin Immunol 1996; 98:895.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carey AB, Cornish K, Schrank P, et al. Cross-reactivity of alternate plant sources of latex in subjects with systemic IgE-mediated sensitivity to Hevea brasiliensis latex. Ann Allergy Asthma Immunol 1995; 74:317.
          </a>
         </li>
         <li class="breakAll">
          Sussman, G, Gold, M. Guidelines for the management of latex allergies and safe latex use in health care facilities. Am College of Allergy Asthma and Immunology 1996. www.acaai.org/public/physicians/latex.htm (Accessed on January 16, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kostyal D, Horton K, Beezhold D, et al. Latex as a significant source of Hevea brasiliensis allergen exposure. Ann Allergy Asthma Immunol 2009; 103:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton RG, Brown RH. Impact of personal avoidance practices on health care workers sensitized to natural rubber latex. J Allergy Clin Immunol 2000; 105:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein DI, Biagini RE, Karnani R, et al. In vivo sensitization to purified Hevea brasiliensis proteins in health care workers sensitized to natural rubber latex. J Allergy Clin Immunol 2003; 111:610.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madan I, Cullinan P, Ahmed SM. Occupational management of type I latex allergy. Occup Med (Lond) 2013; 63:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raulf M, Quirce S, Vandenplas O. Addressing Molecular Diagnosis of Occupational Allergies. Curr Allergy Asthma Rep 2018; 18:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beierwaltes P, Schoessler S. Latex Safe at School: A Student-Centered Approach. NASN Sch Nurse 2017; 32:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gentili A, Lima M, Ricci G, et al. Secondary prevention of latex allergy in children: analysis of results. Pediatr Med Chir 2006; 28:83.
          </a>
         </li>
         <li class="breakAll">
          American Latex Allergy Association www.latexallergyresources.org (Accessed on February 09, 2009).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leynadier F, Herman D, Vervloet D, Andre C. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turjanmaa K, Palosuo T, Alenius H, et al. Latex allergy diagnosis: in vivo and in vitro standardization of a natural rubber latex extract. Allergy 1997; 52:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sastre J, Fernández-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2003; 111:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patriarca G, Nucera E, Pollastrini E, et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002; 95:956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nettis E, Colanardi MC, Soccio AL, et al. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study. Br J Dermatol 2007; 156:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernardini R, Campodonico P, Burastero S, et al. Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study. Curr Med Res Opin 2006; 22:1515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucera E, Schiavino D, Pollastrini E, et al. Sublingual desensitization in children with congenital malformations and latex allergy. Pediatr Allergy Immunol 2006; 17:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lasa Luaces EM, Tabar Purroy AI, García Figueroa BE, et al. Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children. Ann Allergy Asthma Immunol 2012; 108:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cisteró Bahima A, Sastre J, Enrique E, et al. Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract. J Investig Allergol Clin Immunol 2004; 14:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antico A, Pagani M, Crema A. Anaphylaxis by latex sublingual immunotherapy. Allergy 2006; 61:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyukozturk S, Gelincik A, Ozşeker F, et al. Latex sublingual immunotherapy: can its safety be predicted? Ann Allergy Asthma Immunol 2010; 104:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nettis E, Delle Donne P, Di Leo E, et al. Latex immunotherapy: state of the art. Ann Allergy Asthma Immunol 2012; 109:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolland JM, Drew AC, O'Hehir RE. Advances in development of hypoallergenic latex immunotherapy. Curr Opin Allergy Clin Immunol 2005; 5:544.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5554 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12170251" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Management of natural rubber latex allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11994088" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Latex allergy: towards immunotherapy for health care workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21775898" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevention of IgE Sensitization to Latex in Health Care Workers After Reduction of Antigen Exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20659078" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effects of latex avoidance on latex sensitization, atopy and allergic diseases in patients with spina bifida.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18498539" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Latex allergy: a model for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18334054" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Sublingual immunotherapy for latex allergy: tolerability and safety profile of rush build-up phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17383539" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14767458" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of omalizumab in health care workers with occupational latex allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18186440" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : A latex-safe environment is in everyone's best interest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18542027" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Guideline for preventing sensitivity and allergic reactions to natural rubber latex in the workplace.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28888250" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Latex Allergy: Where Are We Now and How Did We Get There?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12602668" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical and occupational outcomes in health care workers with natural rubber latex allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12541209" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reduction of latex sensitisation in spina bifida patients by a primary prophylaxis programme (five years experience).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8182224" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Extractable latex allergens and proteins in disposable medical gloves and other rubber products.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100057" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Extractable latex allergens in airborne glove powder and in cut glove pieces.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079420" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Glove powder reduction and alternative approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16225605" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A study of natural rubber latex allergens in gloves used by healthcare workers in Singapore.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21720169" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Latex medical gloves: time for a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12635427" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : How health care organizations can establish and conduct a program for a latex-safe environment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817368" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Safety of a powder-free latex allergy protocol in the operating theatre: A prospective, observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17573726" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Latex allergy: the sum quantity of four major allergens shows the allergenic potential of medical gloves.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11398071" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16120743" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Administering pharmaceuticals to latex-allergic patients from vials containing natural rubber latex closures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18941629" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Outcome of occupational latex allergy--work ability and quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17845416" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Percutaneous reactivity to natural rubber latex proteins persists in health-care workers following avoidance of natural rubber latex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079417" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Quantitation of latex allergens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28251426" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Occupational Latex Allergy: the Current State of Affairs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079415" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Allergenic proteins of natural rubber latex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12170241" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Allergens and natural rubber proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12170241" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Allergens and natural rubber proteins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21243934" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Estimating allergenicity of latex gloves using Hev b 1 and hevamine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12772945" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : I are we closer to developing threshold limit values for allergens in the workplace?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079416" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Measurement of latex proteins and assessment of latex protein exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079416" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Measurement of latex proteins and assessment of latex protein exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12079416" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Measurement of latex proteins and assessment of latex protein exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8118779" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Composition of synthetic latexes used for manufacturing gloves by dipping processes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8939152" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Absence of cross-reactivity of IgE antibodies from subjects allergic to Hevea brasiliensis latex with a new source of natural rubber latex from guayule (Parthenium argentatum).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7719892" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Cross-reactivity of alternate plant sources of latex in subjects with systemic IgE-mediated sensitivity to Hevea brasiliensis latex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7719892" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cross-reactivity of alternate plant sources of latex in subjects with systemic IgE-mediated sensitivity to Hevea brasiliensis latex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19852202" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Latex as a significant source of Hevea brasiliensis allergen exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10756239" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Impact of personal avoidance practices on health care workers sensitized to natural rubber latex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642845" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : In vivo sensitization to purified Hevea brasiliensis proteins in health care workers sensitized to natural rubber latex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23966436" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Occupational management of type I latex allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29445888" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Addressing Molecular Diagnosis of Occupational Allergies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28777679" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Latex Safe at School: A Student-Centered Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17533902" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Secondary prevention of latex allergy in children: analysis of results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17533902" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Secondary prevention of latex allergy in children: analysis of results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10984382" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9062628" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Latex allergy diagnosis: in vivo and in vitro standardization of a natural rubber latex extract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743562" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Specific immunotherapy with a standardized latex extract in allergic workers: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12351276" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Sublingual desensitization: a new approach to latex allergy problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17493066" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16870076" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Sublingual immunotherapy with a latex extract in paediatric patients: a double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17121589" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Sublingual desensitization in children with congenital malformations and latex allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22541410" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Component-resolved immunologic modifications, efficacy, and tolerance of latex sublingual immunotherapy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15160438" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Tolerance and effects on skin reactivity to latex of sublingual rush immunotherapy with a latex extract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16942577" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Anaphylaxis by latex sublingual immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20408345" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Latex sublingual immunotherapy: can its safety be predicted?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22920069" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Latex immunotherapy: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16264336" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Advances in development of hypoallergenic latex immunotherapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
